For example, patients with a triple-negative breast cancer (TNBC), a subtype that does not express estrogen receptor (ER) and progesterone receptor (PR), and does not overexpress human epidermal growth factor receptor 2 (HER2), are associated with worsened prognosis [2,3]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.